Molecular Pathology & Genomics
To be a world class division of LMP that provides department, collegiate and national leadership in the pursuit of excellence in molecular pathology and genomic research, education and clinical service
To foster a culture of innovation and academic excellence by promoting synergistic collaborations among members of the Division of Molecular Pathology and Genomics
Grand Rounds sponsored by the Division of Molecular Pathology and Genomics
April 11, 2018
- Understand the current use of human pluripotent stem cells for modeling metabolic disease;
- Apply modern gene editing techniques to understand the genetic causes of metabolic diseases
- Develop a strategy to identify novel therapeutics for metabolic disease
May 16, 2018
Lynn Bry, MD, PhD
Associate Pathologist, Brigham and Women’s Hospital
Associate Professor of Pathology
Harvard Medical School
MPG Travel Awards and Great Ideas Awards
The MPG Travel Awards program is designed to encourage presentations in the area of genomics at national/international meetings such as (but not limited to) ASHG, AMP, ACMG and ACLPS that would enhance the visibility of the Division of Molecular Pathology and Genomics.
Applications can be submitted on an ongoing basis and applicants will receive a decision within 2 weeks of submission of an application. The application form can be downloaded here.
The MPG Great Idea Awards program is open to MPG members, trainees, and research lab staff. The due date for applications is October 31st.
MPG Members in the News
MPG member Ken Beckman, director of the U of M Genomics Center, is one of the University researchers behind CoreBiome, Inc., a startup based on patent-pending genomic technology and informatics tools that provide genomic profiles of microbial communities. Microbiomes are proving to be key for understanding human and animal health and disease.
Recent MPG Faculty Publications
Rashidi A, Nelson AC, Linden MA, Weisdorf DJ, Dolan MM, Ustun C. Genomics of clonal evolution in a case of essential thrombocythemia. Leuk Lymphoma. 2017 Jun 11:1-4. doi: 10.1080/10428194.2017.1337113. [Epub ahead of print] PMID: 28604261
Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.J Natl Compr Canc Netw. 2017 Apr;15(4):427-432. PMID:28404754